Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.900
-0.080 (-4.04%)
At close: Aug 25, 2025, 4:00 PM
1.990
+0.090 (4.74%)
After-hours: Aug 25, 2025, 4:15 PM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 3 or -7.50% compared to the previous year.
Employees
37
Change (1Y)
-3
Growth (1Y)
-7.50%
Revenue / Employee
n/a
Profits / Employee
-$649,324
Market Cap
6.25M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37 | -3 | -7.50% |
Dec 31, 2023 | 40 | -5 | -11.11% |
Dec 31, 2022 | 45 | -9 | -16.67% |
Dec 31, 2021 | 54 | -4 | -6.90% |
Dec 31, 2020 | 58 | -22 | -27.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APVO News
- 12 days ago - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Accesswire
- 14 days ago - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Accesswire
- 2 months ago - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers - Accesswire
- 2 months ago - Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 2 months ago - Aptevo More Than Doubles After Favorable Results in Leukemia Study - Market Watch
- 2 months ago - Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer - Benzinga
- 2 months ago - Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire